Major international study to test new heart disease drug

A major international study to test whether a new type of cholesterol treatment can prevent coronary deaths and heart attacks will start in early 2011, it has been announced. The study will be coordinated by the Clinical Trial Service Unit (CTSU) at Oxford University. The REVEAL trial will investigate whether a drug called anacetrapib can drive down the risks of coronary deaths, heart attacks and other vascular complications. The study will involve 30,000 people who have some form of heart or other vascular disease from the UK, North America, China, Germany, Italy, Scandinavia and elsewhere. REVEAL is being funded by Merck Sharp & Dohme, which developed anacetrapib. A grant of £96 million towards the cost of this multi-million dollar study has been provided to the University of Oxford. This is the largest single research contract ever entered into by the University.
account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.

Register


Login

Your Benefits

  • Access to all content
  • Receive newsmails for news and jobs
  • Post ads

myScience